Apollomics has dosed the first participant in a Phase III clinical trial of its new drug, APL-106 (uproleselan injection), in China to treat relapsed or refractory acute myeloid leukaemia (AML) patients.

Uproleselan has been licensed by Apollomics in the Greater China region from GlycoMimetics, which discovered and developed the drug.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The drug can potentially hinder E-selectin from adhering to blood cancer cells, to destroy the leukemic cell resistance mechanism within the bone marrow microenvironment.

The randomised, placebo-controlled, double-blind, bridging trial will assess uproleselan efficacy along with chemotherapy versus chemotherapy alone to treat adult patients with relapsed/refractory AML.

Nealy 140 adults with primary refractory or relapsed AML, who are eligible for induction chemotherapy, will be enrolled in the trial.

Overall survival is the primary goal of the trial while remission rate and duration; and uproleselan’s ability to reduce oral mucositis rate will be included as secondary goals.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company plans to carry out the trial at nearly 20 blood cancer clinical research centres in the country.

This trial is part of Apollomics’ complete development programme in China, which also comprises a Phase I pharmacokinetic and tolerability trial currently underway.

Apollomics co-founder, chairman and CEO Guo-Liang Yu said: “As our first Phase III clinical trial, dosing of the first patient with APL-106 is a major inflection point for Apollomics as we now become a company in late-stage development.

“APL-106 acts via an innovative mechanism that drives cancer cells out of the bone marrow, making them a prime target to be killed by chemotherapy.

“This combined treatment approach could have a meaningful impact on the lives of patients living with relapsed or refractory AML.”

AML is a kind of cancer that affects blood and bone marrow.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now